Education Center

Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome

Funding for this newsletter series was provided by AstraZeneca.

 

The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today.

Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome is the fourth eNewsletter in this series.

Click here to read the supplement.

Next Article: